Objective: To describe the indicidence and severity of iron deficiency anemia (IDA) in patients who have received extracorporeal photopheresis (ECP) treatment of cutaneous T-cell lymphoma (CTCL).
ECP is performed by harvesting mononuclear cells (rich in lymphocytes) from the blood of patients, treating them with 8-MOP, exposing the sensitized cells to UV light outside the body (photoinactivation), and then reintroducing these inactivated cells into the circulation of the patient. A single treatment session consists of 4 to 6 collection cycles plus photoinactivation. A volume of roughly 150 mL of blood (mostly erythrocyte fraction) remains in the older-generation discontinuous-cycle manual ECP equipment (Therakos UVAR XTS) after each treatment and is not returned to the patient. Later-generation continuous-cycle automated ECP equipment (Therakos CELLEX) retains a much smaller volume-approximately a few milliliters per procedure.
ECP is generally regarded as a safe procedure with minimal to no adverse effects. The adverse effects that have been noted are transient and mild, including vasovagal syncope, hematoma and infection at the site of venous access, abnormal clotting (due to heparin flush), headache, fever (4-12 hours after reinfusion of treated cells), and chills. Iron deficiency anemia (IDA) has only infrequently been noted as an adverse effect from ECP in CTCL. 5 A recent review of ECP for treatment of chronic cutaneous GVHD secondary to allogeneic hematopoietic progenitor-cell transplant noted the efficacy of ECP for that disorder but did not mention IDA in its safety profile. 2 Another study 6 of ECP in 82 patients with GVHD found that 3 patients had an increase in red blood cell transfusion requirements but did not report IDA in those patients with long-term ECP.
We noticed that some patients undergoing ECP for treatment of CTCL have developed IDA and require supplementation with intravenous iron infusions. We hypothesize that repeated ECP procedures cause iron deficiency by failing to return to the patient all erythrocytes that are removed during treatment. The goal of this retrospective study was to describe the incidence and severity of IDA in patients treated with ECP for CTCL.
Materials and Methods
We 
Results

Patient Demographics
A total of 36 patients with CTCL treated by ECP were identified; 1 patient was excluded from analysis due to a low initial hemoglobin value of 8.5 g per dL before ECP and multiple red blood cell transfusions during treatment of only 4 ECPs. Of the remaining 35 patients, 22 were men and 13 were women; 20 patients were white and 15 were African American. The number of ECP procedures before development of IDA was determined as the point after which the hemoglobin concentration of a patient followed a definite downward trend. This number of ECPs varied widely, from 2 to 60 procedures, before onset of IDA (median, 11.5; IQR, 3.25-23.0). We observed was no relationship between number of ECPs before onset of IDA and age, sex, ethnicity, body weight, or initial hemoglobin concentration. Because the same patients were treated with the UVAR XTS and CELLEX methods on different dates, it was not possible to show whether these 2 ECP methods had different effects on the development of IDA.
Iron Studies and Treatment
Of the 17 patients who met the criteria for IDA, 8 had had iron studies performed. Serum iron values ranged from 13 to 92 μg per dL (reference range, 30-165 μg/dL), with mean (SD) of 51 (33.4) μg per dL. Transferrin saturation ranged from 3% to 20% (reference range, 16%-60%), with mean % (SD %) of 11.4% (6.2%). Ferritin values ranged from 3 to 33 ng per mL (reference range, 30-330 ng/dL), with mean (SD) of 17.9 (10.4) ng vper mL. These results generally indicated iron deficiency, especially ferritin values ( Table 1 ).
In total, 6 patients received iron supplementation. All of those patients experienced improvement in hemoglobin concentration: 1 patient increased dietary intake of red meat, 1 took oral iron supplements and underwent redblood-cell transfusion, three had 5 intravenous infusions of iron, and one had 10 intravenous infusions of iron.
The case of a patient who developed IDA during ECP treatment, whose condition improved with iron infusions is illustrated in Figure 1 . This 59-year-old African American man initially had slightly reduced hemoglobin concentration and low MCV due to α-thalassemia trait. His hemoglobin and MCV were stable for several months Figure 1A but plateaued at lower values after further ECP procedures ( Figure 1B ). His hemoglobin and MCV then fell more precipitously ( Figure 1C ) but returned to initial values on treatment with iron infusions ( Figure 1D ). This time plot illustrates the usefulness of discovering trends in laboratory values by graphical analysis, for detection of IDA during ECP.
Discussion
This retrospective study demonstrated that extracorporeal photopheresis carries a long-term risk of IDA, most likely due to blood loss when red blood cell mass is retained in the photopheresis equipment and not returned to the patient at the completion of the procedure. Newer ECP continuous flow systems do not retain as much red-bloodcell volume as the older discontinuous flow eqipment. Despite this finding, we could not demonstrate a difference between the 2 systems because patients were not assigned exclusively to only 1 system but instead were treated with both systems on different dates. The incidence of IDA in these patients with CTCL was 49% (17 of 35 patients).
Patients with CTCL are well suited to studying the effect of ECP on IDA because they generally do not have bone marrow involvement and so do not have coincident anemia, which requires frequent transfusions or iron supplementation. In contrast, the other population receiving frequent ECP treatment is recipients of allogeneic hematopoietic stem-cell transplants who develop GVHD. Those patients have multiple possible causes for anemia, including primary malignant neoplasms, chemotherapeutic treatment, delay or failure of engraftment, and direct effects of GVHD. Although ECP could cause IDA in patients with GVHD, these other factors make the association more difficult to recognize in those individuals.
Because not all patients developed IDA, we expected that some characteristic(s) would be associated with IDA; however, IDA was not predicted by patient age, sex, ethnicity, initial hemoglobin concentration, or body weight. Further, the number of ECP procedures before onset of IDA showed no association with patient age, sex, ethnicity, initial hemoglobin, or body weight. Presumably, the tendency to develop IDA and the time during which patients develop it should be related to iron stores, with lower stores predisposing patients to IDA. It is also possible that patients who have high dietary iron intake or who have better absorptive capacity could be more resistant to IDA, even as their iron stores are depleted by red-blood-cell loss from ECP.
Iron deficiency can have many causes, including loss through menses, pregnancy, exercise-induced hemolysis, gastrointestinal-tract bleeding, and failure to absorb adequate iron or dietary deficiency. 7, 8 Although physiologic mechanisms exist to increase iron absorption in the face of deficiency, the resulting state of iron balance depends on rate of iron loss versus rate of iron absorption.
Limitations of this study include that it is a retrospective, observational investigation in which not all patients had iron studies and did not follow the same protocol for diagnosis and treatment of iron deficiency. A strength of this study was the frequency of monitoring of blood counts, which allowed trend analysis of hemoglobin (Hb), MCV, and RDW values to diagnose IDA. Also, these patients were not receiving chemotherapy and did not have other complicating medical conditions leading to anemia, so that the influence of ECP on IDA was clear. These cases also demonstrate the power of evaluating trends in laboratory tests for monitoring patients, rather than merely examining results from a single time point.
A report on treatment of 51 patients with erythrodermic cutaneous T-cell lymphoma with ECP generally administered on 2 consecutive days once a month indicated grade I to II anemia in 3 patients (6%) with no further information on anemia type. 9 In contrast, a more recent report 10 from the Italian registry of therapeutic apheresis, covering 67 apheresis units from 17 Italian regions, documented 486 adverse events (mostly hypocalcemia) in a total of 6738 ECP procedures in 2015 but did not mention anemia or iron deficiency as adverse events.
A recent review 11 of published literature and a consensus statement from the United Kingdom on ECP for treatment of adults and children with acute GVHD noted that ECP is "an extremely safe form of therapy" with infrequent significant reactions. This report did not mention anemia or iron deficiency as an adverse effect from ECP. Another recent review article 12 indicated that ECP is becoming more widely applied in prevention and treatment of acute GVHD due to its high potential for effectiveness and low risk of adverse events, presumably because ECP is immunomodulatory rather than immunosuppressive.
The conclusion of these recent reports is that ECP is preferable to alternative treatments due to its effectiveness and minimal adverse effects. Within this setting, it is prudent for physicians practicing ECP to be aware of its potential for inducing IDA, which can be readily treated with iron infusions.
